Checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to predict who these patients are and — just as important — who they aren’t. But results from a new study could help improve those forecasts.
For 25 years, scientists in the Pacific Northwest Prostate Cancer SPORE, an NCI-funded center of research excellence, have made life-saving insights into prostate cancer biology.…
The V Foundation for Cancer Research has awarded Fred Hutchinson Cancer Research Center computational biologist Dr. Gavin Ha a 2019 V Scholar Grant to study…
Research by Fred Hutch Cancer Center genetic epidemiologist Burcu Darst, PhD, and scientists from the Canary Prostate Active Surveillance Study (PASS), suggests that a patient’s…
Survival rates of prostate cancer are based on outcomes of people who’ve had the disease. Find the survival rates for prostate cancer here.
Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair…
Fred Hutch Prostate Cancer Screening and Early Detection offer screening and testing.
Approximately 1.5 million new cases of prostate cancer are diagnosed annually worldwide. Approximately 75% of patients present with cancer localized to the prostate, which is…
During one of the most active flu seasons in recent memory, infectious disease experts at Fred Hutch Cancer Center say many of the public health…
Format Live, In-Person Event *Pre-registration required Live interactive continuing medical education activity for healthcare professionals in Renton, Seattle, Tacoma, and surrounding areas to discuss multiple myeloma…
Fred Hutch is integrating a new artificial intelligence (AI) technology, GI Genius, into colonoscopy scans to help evaluate suspicious polyps.
